Article
Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study.
The pharmacogenomics journal - 1 Apr 2020
Clemens Eva, Broer Linda, Langer Thorsten, Uitterlinden André G, de Vries Andrica C H, van Grotel Martine, Pluijm Saskia F M, Binder Harald, Byrne Julianne, Broeder Eline van Dulmen-den, Crocco Marco, Grabow Desiree, Kaatsch Peter, Kaiser Melanie, Kenborg Line, Winther Jeanette F, Rechnitzer Catherine, Hasle Henrik, Kepak Tomas, van der Kooi Anne-Lotte F, Kremer Leontien C, Kruseova Jarmila, Kuehni Claudia E, van der Pal Heleen, Parfitt Ross, Deuster Dirk, Matulat Peter, Spix Claudia, Tillmanns Amelie, Tissing Wim J E, Maier Lara, Am Zehnhoff-Dinnesen Antoinette, Zolk Oliver, van den Heuvel-Eibrink Marry M
Abstract excerpt
Ototoxicity is a common side effect of platinum treatment and manifests as irreversible, high-frequency sensorineural hearing loss. Genetic association studies have suggested a role for SNPs in genes related to the disposition of cisplatin or deafness. In this study, 429 pediatric patients that were treated with cisplatin were genotyped for 10 candidate SNPs. Logistic regression analyses revealed that younger age...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.